Nat Commun:眼部免疫细胞有望治疗视网膜病变

2017-10-10 佚名 新华社

澳大利亚莫纳什大学研究人员首次发现,眼部也存在免疫细胞。这一发现有望为早产儿视网膜病变、糖尿病视网膜病变等新生血管性视网膜病变提供新疗法。

澳大利亚莫纳什大学研究人员首次发现,眼部也存在免疫细胞。这一发现有望为早产儿视网膜病变、糖尿病视网膜病变等新生血管性视网膜病变提供新疗法。

莫纳什大学中央临床学院糖尿病系的研究人员发现,具有抗病功能的免疫细胞——调节性T细胞存在于人的视网膜中。研究人员之一、珍妮弗·威尔金森·贝尔卡教授说,眼睛和大脑一样有某种屏障,人们过去认为眼组织中不会有免疫细胞。她认为,这道屏障是有弱点的,可以让T细胞进入。

研究人员在新一期英国《自然·通讯》杂志上报告说,视网膜中的调节性T细胞可以修补受损的视网膜血管。在动物实验中,研究人员增强了调节性T细胞的活性,使早产儿视网膜病变的症状显着减轻,他们目前已经开始进行小规模临床试验。

新生血管性视网膜病变是指视网膜表面长出新的、异常的血管。随着病程进展,这些新生血管会渗漏、破裂甚至导致视网膜脱落,诱发视力受损乃至失明。其中,早产儿视网膜病变常见于早产儿,是婴儿视力减退甚至失明的主要原因。该病目前主要用激光手术治疗,但激光在阻止异常血管生长的同时也会对健康细胞造成损害,治疗后病情也可能继续恶化。

原始出处:

Deliyanti, D., et al., Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nat Commun, 2017. 8(1): p. 748.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087143, encodeId=035b208e1431f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 03 00:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882497, encodeId=d82d188249ec4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 16 19:51:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776057, encodeId=e97a1e76057fa, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Mar 06 05:51:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269956, encodeId=7cf212699565a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413913, encodeId=797d14139135c, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-04-03 zhouqu_8
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087143, encodeId=035b208e1431f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 03 00:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882497, encodeId=d82d188249ec4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 16 19:51:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776057, encodeId=e97a1e76057fa, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Mar 06 05:51:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269956, encodeId=7cf212699565a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413913, encodeId=797d14139135c, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-09-16 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087143, encodeId=035b208e1431f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 03 00:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882497, encodeId=d82d188249ec4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 16 19:51:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776057, encodeId=e97a1e76057fa, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Mar 06 05:51:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269956, encodeId=7cf212699565a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413913, encodeId=797d14139135c, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-03-06 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087143, encodeId=035b208e1431f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 03 00:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882497, encodeId=d82d188249ec4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 16 19:51:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776057, encodeId=e97a1e76057fa, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Mar 06 05:51:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269956, encodeId=7cf212699565a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413913, encodeId=797d14139135c, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2017-10-12 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087143, encodeId=035b208e1431f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Apr 03 00:51:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882497, encodeId=d82d188249ec4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 16 19:51:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776057, encodeId=e97a1e76057fa, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Mar 06 05:51:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269956, encodeId=7cf212699565a, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413913, encodeId=797d14139135c, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Oct 12 02:51:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]

相关资讯

Science Advances:免疫细胞“呕吐”,阻止病原菌感染

8月16日,《Science Advances》期刊最新发表一篇文章“Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5”,揭示了一种阻止致命真菌“劫持”免疫细胞入侵大脑的方法。

Nature:一周后又一篇DNA损伤机制!癌症免疫联合治疗的希望

一周前,对细胞如何检测DNA损伤的新见解于7月24日在线发表在Nature上。解释了为什么与DNA结合的一个叫cGAS(环GMP–AMP合成酶)的关键分子会因DNA损害和自体免疫失调而引发炎症。cGAS可以DNA破损形成的微核和DNA结合,启动导致炎症的机制(详细)。而一周后同样的关键词cGAS和微核又出现在Nature在线发表的文章,DNA损伤造成炎症的相关研究有了下篇。

SCI TRANSL MED :特定的T细胞,过敏的罪魁祸首

花粉、花生、牛奶、宠物毛、螨虫、青霉素、霉菌……很多看似寻常且无害的物品对于一些人而言,却是不得不避免的过敏原。这些物质会促使免疫系统过激反应,造成一系列过敏性伤害。 当免疫系统对过敏原发生错误的判断,做出过激的反应,即会导致过敏。这些症状的罪魁祸首是一组辅助T细胞——TH2细胞。但是,并不是所有的TH2细胞都是“有罪”的,甚至于一些TH2细胞负责保护机体免于病原体的入侵,发挥着关键作用。

Oncotarget:免疫细胞的“背叛”极大增加了我们的患癌风险!

儿童医院洛杉矶儿童癌症和血液病儿童研究中心的调查人员已经确定了关于免疫细胞(称为肿瘤相关巨噬细胞)的新发现,其促进癌症而不是抗击它。他们已经确定了分子途径,称为STAT3,作为免疫细胞用于促进神经母细胞瘤(小儿癌症)的机制,并且已经证明使用临床上可用的药物鲁木菌素来阻断该途径。研究结果于9月20日刊登在Oncotarget杂志上。

Nat Commun:研究揭示膀胱癌治疗效果不佳的重要原因!

新研究提供了一个可能的解释,为什么一种新型的癌症治疗方法未能像预期的那样对膀胱癌起作用。

J Clin Invest:研究发现帮助对抗侵袭性乳腺癌的免疫细胞!

乳腺癌仍然是美国妇女与癌症相关死亡的主要原因。早期检测和靶向治疗改善了整体患者的疗效,但这些因素也深刻影响了预后。缺乏雌激素,孕激素和人类表皮生长因子2(HER2)激素受体表达的所谓“三阴”乳腺癌不能被现有的激素治疗所靶向,患者生存率差。三阴性乳腺癌的claudin-low亚型的特征在于其特异性较差的预后,以及肿瘤微环境中免疫细胞浸润的显著更高的速率。虽然观察结果表明,乳腺癌亚型中免疫浸润与患者预